Incyte, Syndax Gets FDA Clearance for Niktimvo 9mg and 22mg Vials


Products or drugs approved by the FDA

Olivier Le Moal

Incentive (NASDAQ:INCY) and Syndax Pharmaceuticals (SNDX) have received FDA approval for their drug Niktimvo in 9 mg and 22 mg vial sizes.

Niktimvo was approved in August 2024 for the treatment of chronic graft-versus-host disease after failure of at least



Source link

  • Related Posts

    December Australian employment rises above previous forecasts, a near-term rate cut looks possible

    By Stella Qiu SYDNEY (Reuters) – Australian employment accelerated earlier forecasts in December, even as the unemployment rate rose as many more people went looking for work, the combination of…

    Vorwerk Group SE stock rose on strong sales growth By Investing.com

    Investing.com — Shares of Vorwerk Group SE rose 3% today after the company announced a 59% year-over-year (YoY) sales increase and a significant improvement of EBITDA margin. The company’s recovery…

    Leave a Reply

    Your email address will not be published. Required fields are marked *